<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">agx</journal-id><journal-title-group><journal-title xml:lang="ru">Андрология и генитальная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Andrology and Genital Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-9781</issn><issn pub-type="epub">2412-8902</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62968/2070-9781-2024-25-4-47-54</article-id><article-id custom-type="elpub" pub-id-type="custom">agx-800</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group></article-categories><title-group><article-title>Исследование тестостерона крови у пациентов с хроническим простатитом</article-title><trans-title-group xml:lang="en"><trans-title>Study of blood testosterone in patients with chronic prostatitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6948-6075</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калинкин</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalinkin</surname><given-names>D. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калинкин Дмитрий Евгеньевич - профессор кафедры общей и детской урологии-андрологии; заведующий отделением общей и детской урологии, д-р мед. наук, доцент</p><p>634050 Томск, Московский Тракт, 2; 634034, Томск, Котовского, 19</p><p>РИНЦ 8348-2698</p><p>телефон: +79234406136</p></bio><bio xml:lang="en"><p>Kalinkin Dmitry Evgenievich</p><p>634050, Tomsk, Moskovsky Trakt, 2; 634034, Tomsk, Kotovsky, 19</p></bio><email xlink:type="simple">kalinkin750@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бощенко</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Boshchenk</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бощенко Вячеслав Семенович - заведующий кафедрой общей и детской урологии-андрологии, д-р мед. наук, доцент</p><p>634050 Томск, Московский Тракт, 2; 634034, Томск, Котовского, 19</p></bio><bio xml:lang="en"><p>634050, Tomsk, Moskovsky Trakt, 2; 634034, Tomsk, Kotovsky, 19</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО СибГМУ Минздрава России; Группа Компаний «Здоровье»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education Siberian State Medical University of the Ministry of Health of the&#13;
Russian Federation; Health Group of Companies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>01</month><year>2025</year></pub-date><volume>25</volume><issue>4</issue><fpage>47</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калинкин Д.Е., Бощенко В.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Калинкин Д.Е., Бощенко В.С.</copyright-holder><copyright-holder xml:lang="en">Kalinkin D.E., Boshchenk V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://agx.elpub.ru/jour/article/view/800">https://agx.elpub.ru/jour/article/view/800</self-uri><abstract><sec><title>Введение</title><p>Введение: хронический простатит – полиэтиологичное заболевание со сложным патогенезом, значительно снижающее качество жизни мужчины. Одним из факторов патогенеза простатита является дефицит тестостерона, однако его роль требует дальнейшего изучения.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: изучить уровень тестостерона и его взаимосвязь с основными клинико-лабораторными и инструментальными показателями у пациентов с хроническим простатитом.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: выполнен ретроспективный анализ результатов обследования 393 пациентов, страдающих хроническим простатитом (категории II, IIIA и IIIB по классификации NIH, 1995). Средний возраст пациентов составил 44,33±10,01 года. Оценивалась статистическая значимость различия (p) суммы баллов по шкале NIH-CPSI, содержания лейкоцитов и патогенной микрофлоры в секрете предстательной железы, максимальной объемной скорости мочеиспускания и объема остаточной мочи у пациентов с содержанием тестостерона крови &lt;8, 8-12 и &gt;12 нмоль/л. Также оценивалась взаимосвязь (коэффициент корреляции, r) между уровнем тестостерона и перечисленными показателями. Критерием исключения для пациентов в возрасте 50 лет и старше (при наличии семейного анамнеза – 45 лет и старше) было наличие подозрения на рак предстательной железы.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования: доля пациентов, имевших уровень тестостерона менее 12 нмоль/л, составила 31,04%. Средний уровень тестостерона крови был выше порогового значения (12 нмоль/л) и статистически значимо не отличался у пациентов с разными категориями ХП/СХТБ. У пациентов с содержанием тестостерона крови &lt;8 нмоль/л содержание лейкоцитов в секрете предстательной железы было статистически значимо выше, чем у пациентов других групп (p&lt; 0,05) ; кроме того, у пациентов с содержанием тестостерона крови менее 8 нмоль/л выявлена наименьшая объемная скорость мочеиспускания и наибольший объем остаточной мочи (в сравнении с двумя другими группами), однако данное различие было статистически незначимым (p&gt;0,05). Выявлена отрицательная корреляция между уровнем тестостерона, с одной стороны, и количеством баллов по шкале NIH-CPSI и содержанием лейкоцитов в секрете предстательной железы, с другой.</p></sec><sec><title>Заключение</title><p>Заключение: необходимо продолжить исследование на расширенной когорте пациентов с целенаправленным формированием групп с низким и «субнормальным» содержанием тестостерона крови.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction: Chronic prostatitis is a polyetiological disease with a complex pathogenesis, significantly reducing the quality of life of men. One of the factors in the pathogenesis of prostatitis is testosterone deficiency, but its role requires further study.</p></sec><sec><title>Purpose of the study</title><p>Purpose of the study: to study the level of testosterone and its relationship with the main clinical, laboratory and instrumental parameters in patients with chronic prostatitis.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods: A retrospective analysis of the examination results of 393 patients suffering from chronic prostatitis (categories II, IIIA and IIIB according to the NIH classification, 1995) was performed. The average age of the patients was 44.33±10.01 years. The statistical significance of the difference (p) in the sum of points on the NIH-CPSI scale, the content of leukocytes and pathogenic microflora content in the secretion of the prostate gland, the maximum volumetric flow rate of urination and the volume of residual urine in patients with blood testosterone levels &lt; 8 , 8-12 and &gt;12 nmol/l was estimated. The relationship (correlation coefficient, r) between testosterone levels and the above parameters was also assessed.</p></sec><sec><title>Study results</title><p>Study results: the proportion of patients with testosterone levels below 12 nmol/L was 31.04%. The average blood testosterone level was above the threshold (12 nmol/L) and did not differ statistically significantly in patients with different CP/CPPS categories. In patients with blood testosterone levels &lt; 8 nmol/L, the white blood cell count in prostate secretions was statistically significantly higher than in patients in other groups (p&lt;0.05); in addition, patients with blood testosterone levels below 8 nmol/L had the lowest urinary flow rate and the highest residual urine volume (compared to the other two groups), but this difference was not statistically significant (p &gt;0.05). A negative correlation was found between the testosterone level, on the one hand, and the number of points on the NIH-CPSI scale and the content of leukocytes in the prostate gland secretion, on the other.</p></sec><sec><title>Conclusion</title><p>Conclusion: it is necessary to continue the study on an expanded cohort of patients with the targeted formation of groups with low and «subnormal» blood testosterone content.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>тестостерон</kwd><kwd>хронический простатит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>testosterone</kwd><kwd>chronic prostatitis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено без спонсорской поддержки.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Черный А.А. Особенности клинического течения и лечения хронического бактериального простатита. Автореф. дис. … канд. мед. наук. Ростов-на-Дону, 2015. 22 с.</mixed-citation><mixed-citation xml:lang="en">Черный А.А. Особенности клинического течения и лечения хронического бактериального простатита. Автореф. дис. … канд. мед. наук. Ростов-на-Дону, 2015. 22 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshihisa Matsukawa, Yasuhito Funahashi, Shohei Ishida et al. Clinical features and urodynamic findings in eldery men with chronic prostatitis. Int J Urol. 2022 May; 29 (5): 441-445. PMID: 35146792. DOI: 10.1111/iju.14805.</mixed-citation><mixed-citation xml:lang="en">Yoshihisa Matsukawa, Yasuhito Funahashi, Shohei Ishida et al. Clinical features and urodynamic findings in eldery men with chronic prostatitis. Int J Urol. 2022 May; 29 (5): 441-445. PMID: 35146792. DOI: 10.1111/iju.14805.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Min Ho Lee, Deok Ha Seo, Chun Woo Lee et al. Relationship between Hypogonadal Symptoms, Sexual Dysfunction and Chronic Prostatitis in Middle-Aged Men by Self-Reported Questionnaires, even without Biochemical Testosterone Deficiency. World J Mens Health 2020 Apr;38(2):243-249. PMID: 32180375. DOI: 10.5534/wjmh.190117.</mixed-citation><mixed-citation xml:lang="en">Min Ho Lee, Deok Ha Seo, Chun Woo Lee et al. Relationship between Hypogonadal Symptoms, Sexual Dysfunction and Chronic Prostatitis in Middle-Aged Men by Self-Reported Questionnaires, even without Biochemical Testosterone Deficiency. World J Mens Health 2020 Apr;38(2):243-249. PMID: 32180375. DOI: 10.5534/wjmh.190117.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chen-Hsun Ho, Yu-Chuan Lu, Chia-Kwung Fan et al. Testosterone regulates the intracellular bacterial community formation of uropathogenic Escherichia coli in prostate cells via STAT3. Int J Med Microbiol. 2020 Oct;310(7):151450. PMID: 33092696. DOI: 10.1016/j.ijmm.2020.151450.</mixed-citation><mixed-citation xml:lang="en">Chen-Hsun Ho, Yu-Chuan Lu, Chia-Kwung Fan et al. Testosterone regulates the intracellular bacterial community formation of uropathogenic Escherichia coli in prostate cells via STAT3. Int J Med Microbiol. 2020 Oct;310(7):151450. PMID: 33092696. DOI: 10.1016/j.ijmm.2020.151450.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nur-Vaizura Mohamad, Sok Kuan Wong, Wan Nuraini Wan Hasan et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male 2019 Jun;22(2):129- 140. PMID: 29925283. DOI: 10.1080/13685538.2018.1482487</mixed-citation><mixed-citation xml:lang="en">Nur-Vaizura Mohamad, Sok Kuan Wong, Wan Nuraini Wan Hasan et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male 2019 Jun;22(2):129- 140. PMID: 29925283. DOI: 10.1080/13685538.2018.1482487</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vinarov A.Z., Rozhivanov R.V. Effect of transdermal testosterone on the quality of life of men with androgen deficiency and chronic prostatitis in routine clinical practice. Urologiia 2018 Mar:(1):71- 76. PMID: 29634137</mixed-citation><mixed-citation xml:lang="en">Vinarov A.Z., Rozhivanov R.V. Effect of transdermal testosterone on the quality of life of men with androgen deficiency and chronic prostatitis in routine clinical practice. Urologiia 2018 Mar:(1):71- 76. PMID: 29634137</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yuki Kato, Kazuyoshi Shigehara, Shohei Kawaguchi et al. Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: a subanalysis of a prospective randomised controlled study in Japan (EARTH study). Andrologia 2020 Oct; 52(9): e13768. DOI: 10.1111/and.13768. PMID: 32706428</mixed-citation><mixed-citation xml:lang="en">Yuki Kato, Kazuyoshi Shigehara, Shohei Kawaguchi et al. Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: a subanalysis of a prospective randomised controlled study in Japan (EARTH study). Andrologia 2020 Oct; 52(9): e13768. DOI: 10.1111/and.13768. PMID: 32706428</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">G Rastrelli, S Cipriani, F Lotti, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest. 2022 Jul;45(7):1413-1425. PMID: 35298833. DOI: 10.1007/s40618-022-01776-9.</mixed-citation><mixed-citation xml:lang="en">G Rastrelli, S Cipriani, F Lotti, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest. 2022 Jul;45(7):1413-1425. PMID: 35298833. DOI: 10.1007/s40618-022-01776-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Aksam Yassin, Joanne E Nettleship, Raidh A Talib et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016; 19(1):64-9. DOI: 10.3109/13685538.2015.1126573 PMID: 26742589</mixed-citation><mixed-citation xml:lang="en">Aksam Yassin, Joanne E Nettleship, Raidh A Talib et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016; 19(1):64-9. DOI: 10.3109/13685538.2015.1126573 PMID: 26742589</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Коган, М.И., Авадиева Н.Э., Геворкян Л.С. и др. Результаты многоцентрового проспективного сравнительного исследования препарата Андрогель® у мужчин с недостаточностью эндогенного тестостерона и симптомами нижних мочевых путей при доброкачественной гиперплазии предстательной железы («Поток»). Урология 2023; 2:32-40. Doi: https: //dx.doi.org/10.18565/urology.2023.2.32-40</mixed-citation><mixed-citation xml:lang="en">Коган, М.И., Авадиева Н.Э., Геворкян Л.С. и др. Результаты многоцентрового проспективного сравнительного исследования препарата Андрогель® у мужчин с недостаточностью эндогенного тестостерона и симптомами нижних мочевых путей при доброкачественной гиперплазии предстательной железы («Поток»). Урология 2023; 2:32-40. Doi: https: //dx.doi.org/10.18565/urology.2023.2.32-40</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ilpo T Huhtaniemi, Abdelouahid Tajar, David M Lee et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012 Jun;166(6):983-91. DOI: 10.1530/EJE-11-1051. PMID: 22423144.</mixed-citation><mixed-citation xml:lang="en">Ilpo T Huhtaniemi, Abdelouahid Tajar, David M Lee et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012 Jun;166(6):983-91. DOI: 10.1530/EJE-11-1051. PMID: 22423144.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Araujo, A.B. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2011. 96: 3007. DOI: 10.1210/jc.2011-1137 PMID: 21816776</mixed-citation><mixed-citation xml:lang="en">Araujo, A.B. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2011. 96: 3007. DOI: 10.1210/jc.2011-1137 PMID: 21816776</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wu, F.C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med, 2010. 363: 123. DOI: 10.1056/NEJMoa0911101 PMID: 20554979</mixed-citation><mixed-citation xml:lang="en">Wu, F.C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med, 2010. 363: 123. DOI: 10.1056/NEJMoa0911101 PMID: 20554979</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zarotsky, V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology, 2014. 2: 819. DOI: 10.1111/andr.274 PMID: 25269643</mixed-citation><mixed-citation xml:lang="en">Zarotsky, V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology, 2014. 2: 819. DOI: 10.1111/andr.274 PMID: 25269643</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
